Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Cantor Fitzgerald
Harvard Business School
US Department of Justice
Medtronic

Generated: May 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,147,095

« Back to Dashboard

Which drugs does patent 6,147,095 protect, and when does it expire?

Patent 6,147,095 protects APTIVUS and is included in two NDAs.

Protection for APTIVUS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 6,147,095
Title: Method for improving the pharmacokinetics of tipranavir
Abstract:The present invention relates to a novel method for improving the pharmacokinetics of tipranavir, comprising administering to a human in need of such treatment a combination of a therapeutically effective amount of tipranavir or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of ritonavir or a pharmaceutically acceptable salt thereof.
Inventor(s): Ferry; James J. (Kalamazoo, MI), Baldwin; John R. (Portage, MI), Borin; Marie T. (Kalamazoo, MI)
Assignee: Pharmacia & Upjohn Company (Kalamazoo, MI)
Application Number:09/430,742
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,147,095
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,147,095

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 6,147,095

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1440400 ➤ Try a Free Trial
Australia 762349 ➤ Try a Free Trial
Brazil 9914940 ➤ Try a Free Trial
Canada 2346131 ➤ Try a Free Trial
China 1154491 ➤ Try a Free Trial
China 1324237 ➤ Try a Free Trial
Colombia 5160321 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Army
McKinsey
Mallinckrodt
McKesson
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.